株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

CountryFocus:シンガポールの医療・規制・医療費償還制度の状況

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Singapore

発行 GlobalData 商品コード 321243
出版日 ページ情報 英文 182 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.89円で換算しております。
Back to Top
CountryFocus:シンガポールの医療・規制・医療費償還制度の状況 CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Singapore
出版日: 2017年06月01日 ページ情報: 英文 182 Pages
概要

シンガポールの人口は、平均余命の改善などの影響により、2008年には480万人、2013年には540万人と増加し続けています。それに合わせて、医薬品市場も2008年には4億8900万米ドル、2013年には7億6100万米ドル、その間の年平均成長率(CAGR)は9.3%、と拡大傾向が続いています。また、2014年の市場規模は7億7600万米ドル、2020年には8億7300万米ドル、2014〜2020年のCAGRは2.0%、と推計されています。一方、医療技術部門の生産高は2011年には43億シンガポールドル(34億米ドル)に達し、更に2015年には50億シンガポールドル(40億米ドル)にまで拡大する見通しです。政府の積極的な支援策や大学での活発な研究活動が、医療関連市場のプラス成長に貢献しています。

当レポートでは、シンガポールの医療関連市場の動向や、医療費償還制度およびその他の関連規制・制度について分析し、医薬品産業・医療装置産業の全体的構造・動向、医療費償還制度やその周辺の保険市場の動向、医療規制当局の構造や各種規制の概要、シンガポール経済・社会に関するマクロ的指標(医療インフラなど)、今後の市場機会と課題といった情報を取りまとめて、概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

第3章 医薬品・医療機器市場の概要

  • 医薬品市場
    • 市場概要
    • 医薬品の輸出入
    • 供給チャネル
    • 市場の分類
    • 主な疾患分野
    • 主な参入企業
  • 医療装置市場
    • 市場概要
  • 市場の促進要因と障壁
    • 促進要因
    • 参入障壁

第4章 市場へのアクセス

  • 医療費償還・保険料支払者の状況
    • 医療制度の概要
    • 医療費償還プロセス
    • 保険事業者の概要
    • 医療費支出に対する患者負担の比率
    • 医療サービスの価格動向
    • 薬価政策
  • 規制状況
    • 規制当局の概要
    • 医薬品の市販承認過程
    • 新しい医療装置の承認過程
    • 医療機器の新製品の認証過程
    • 輸出入
    • 知的所有権
    • 治験関連の規制
    • 医薬品の広告に関する規制
    • 薬局関連の規制
    • ラベリング・包装に関する規制

第5章 国別分析

  • 政治的環境
    • 政治的構造
    • 現在の政治的環境に関する分析
    • 医療関連の政策的取り組み
  • 経済情勢
  • 経済指標
    • 国内総生産(GDP)
    • 国民総所得
    • インフレーション
    • 為替レート
    • 海外直接投資
    • 外貨準備金
    • 貿易収支
    • 政府の構造バランス
    • 国債発行総額
    • 主要産業
  • 人口統計
    • 人口
    • 教育および識字率
    • 就労状況
    • 疾患負荷
  • 医療インフラ
    • 医療設備
    • 医療パラメーター
    • 環境衛生
    • 医療人材
  • 医療費
    • 概要
    • 公共/民間部門のシェア
    • 医療費支出の主な内容
    • 医薬品の研究開発への支出額
  • 産業団体
  • 見本市

第6章 市場機会および課題

  • 市場機会
  • 課題

第7章 付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC0074CHR

Singapore is known for its world-class biomedical science research facilities and develops pharmaceuticals and medical devices at the medical technology hubs MedTech, Biopolis and Tuas Biomedical Park. The country has emerged as a regional hub for the manufacture and R&D activities of multinational pharmaceutical companies, and offers excellent opportunities for Biomedical Science (BMS) companies via a pro-business environment, low unit labor costs, low corporate tax, and strong government support.

Singapore's healthcare market is driven by universal access to health insurance schemes and world-class biomedical sciences research facilities, although the market is small in comparison to those of other developed countries, primarily due to the small population. The value of the pharmaceuticals market increased from Us$642m in 2009 to Us$903m in 2016 at a Compound Annual Growth Rate (CAGR) of 5% and is expected to increase from 2017 to 2021 at a CAGR of 5%.

In 2010, Singapore was ranked fourth globally for its healthcare infrastructure. The MoH is responsible for providing for the healthcare service needs of the people, through policy planning and co-ordination. Singapore's healthcare institutions consist of public hospitals, private hospitals and specialty centers, covering the entire spectrum of clinical services, from basic health screening to dental surgery and quaternary care. In 2009, the public sector health expenditure share was 35.7%, which increased to an estimated 44.4% in 2016 at a CAGR of 3% (World Bank, 2017q). This is expected to drive the country's healthcare market.

The report "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Singapore" is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in Singapore. It identifies the key trends in the country's healthcare market and provides insights into its demographic, regulatory, and reimbursement landscape and healthcare infrastructure.

In particular, this report -

  • Provides an overview of the pharmaceutical and medical device market of Singapore, including the market size; market segmentation by generic, Over-The-Counter (OTC), biologic and biosimilar products; and the key drivers and barriers for the market. The section also includes profiles of the major companies, including a SWOT assessment.
  • Covers the country's reimbursement and payer landscape, as well as the regulatory landscape. The reimbursement and payer landscape section elaborates on the features of the healthcare reimbursement process for Singapore.
  • Provides a detailed analysis of the political and economic environment of Singapore. It analyzes its economic indicators, demographics, healthcare infrastructure and healthcare expenditure.
  • Provides an overview of the opportunities and challenges for growth that exist in the healthcare market of Singapore.

Scope

The report provides information on the healthcare, regulatory, and reimbursement landscape in Singapore, and includes -

  • An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers
  • Profiles and SWOT analyses of the major players in the pharmaceutical market: Merck & Co., Sanofi, Hyphens Pharma, Novartis, and Valeant.
  • An insightful review of the reimbursement and regulatory landscape, with analysis covering details of the country's healthcare reimbursement process, regulatory agencies and the approval processes for new drugs and medical devices
  • Detailed analysis of the country's political and economic environment, covering economic indicators, demographics, healthcare infrastructure and healthcare expenditure
  • An overview of the opportunities for and challenges to growth in the Singaporean healthcare market

Reasons to buy

This report will enhance your decision-making capability by allowing you to -

  • Develop business strategies by understanding the trends shaping and driving Singapore's healthcare market
  • Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments and companies likely to impact Singapore's healthcare market in the future
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing competitors' performance
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment and strategic partnership

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 4
  • 1.2 List of Figures 6

2 Executive Summary 8

3 Introduction 12

  • 3.1 GlobalData Report Guidance 12

4 Overview of Pharmaceutical and Medical Device Markets 13

  • 4.1 Pharmaceutical Market 13
    • 4.1.1 Market Overview 13
    • 4.1.2 Pharmaceutical Exports and Imports 17
    • 4.1.3 Supply Channels 18
    • 4.1.4 Market Segments 18
    • 4.1.5 Overview of Major Disease Areas 20
    • 4.1.6 Major Players 22
  • 4.2 Medical Device Market 51
    • 4.2.1 Market Overview 51
  • 4.3 Market Drivers and Barriers 52
    • 4.3.1 Drivers 52
    • 4.3.2 Barriers 52

5 Market Access 54

  • 5.1 Overview of Healthcare System 54
    • 5.1.1 Reimbursement Process 56
    • 5.1.2 Overview of Insurance Providers 57
    • 5.1.3 Patient Share in Healthcare Expenditure 61
    • 5.1.4 Price Trends in the Healthcare Sector 61
    • 5.1.5 Pricing Policies 62
  • 5.2 Regulatory Landscape 63
    • 5.2.1 Overview of Regulatory Agencies 63
    • 5.2.2 Market Authorization Procedure for Pharmaceutical Products 66
    • 5.2.3 New Medical Device Approval Process 70
    • 5.2.4 Licensing Process for Pharmaceutical and Medical Device Manufacturing 72
    • 5.2.5 Exports and Imports 74
    • 5.2.6 Intellectual Property Rights 77
    • 5.2.7 Clinical Trial Regulations 88
    • 5.2.8 Pharmaceutical Advertising Regulations 92
    • 5.2.9 Pharmacy Regulations 94
    • 5.2.10 Labeling and Packaging Regulations 94

6 Country Analysis 98

  • 6.1 Political Environment 98
    • 6.1.1 Current Political Environment 99
    • 6.1.2 Healthcare Policy Initiatives 99
  • 6.2 Economic Landscape 101
  • 6.3 Economic Indicators 105
    • 6.3.1 Gross Domestic Product 105
    • 6.3.2 Gross National Income 109
    • 6.3.3 Inflation 110
    • 6.3.4 Currency Exchange Rate 114
    • 6.3.5 Foreign Direct Investment 115
    • 6.3.6 Foreign Exchange Reserves 116
    • 6.3.7 Trade Balance 117
    • 6.3.8 Government Structural Balance 119
    • 6.3.9 Government Net Debt 120
    • 6.3.10 Major Industries 122
  • 6.4 Demographics 123
    • 6.4.1 Population 123
    • 6.4.2 Education and Literacy 139
    • 6.4.3 Employment 141
    • 6.4.4 Disease Burden 141
  • 6.5 Healthcare Infrastructure 143
    • 6.5.1 Healthcare Facilities 143
    • 6.5.2 Healthcare Parameters 147
    • 6.5.3 Environmental Health 148
    • 6.5.4 Healthcare Personnel 150
  • 6.6 Healthcare Expenditure 153
    • 6.6.1 Overview 153
    • 6.6.2 Share of Public and Private Sectors 154
    • 6.6.3 Major Components of Healthcare Expenditure 155
    • 6.6.4 Spending in Pharmaceutical R&D 156
  • 6.7 Trade Associations 157
    • 6.7.1 The Singapore Association of Pharmaceutical Industries 157
    • 6.7.2 The Singapore Medical Association 158
    • 6.7.3 The Society for Emergency Medicine in Singapore 158
    • 6.7.4 The Pharmaceutical Society of Singapore 158
    • 6.7.5 The Healthcare Quality Society of Singapore 159
  • 6.8 Trade Fairs 160

7 Opportunities and Challenges 161

  • 7.1 Opportunities 161
  • 7.2 Challenges 162

8 Appendix 163

  • 8.1 Abbreviations 163
  • 8.2 Bibliography 167
  • 8.3 Research Methodology 180
    • 8.3.1 Coverage 180
    • 8.3.2 Secondary Research 180
    • 8.3.3 Forecasts 181
    • 8.3.4 Expert Panel 181
  • 8.4 Contact Us 181
  • 8.5 Disclaimer 182

List of Tables

1.1 List of Tables

  • Table 1: Pharmaceutical Market, Singapore, Revenue ($m), 2009-2016 15
  • Table 2: Pharmaceutical Market, Singapore, Revenue ($m), 2017-2021 16
  • Table 3: Pharmaceutical Market, Singapore, Exports and Imports ($bn), 2009-2016 17
  • Table 4: Pharmaceutical Market, Merck & Co., Global, Major Products, 2017 23
  • Table 5: Pharmaceutical Market, Merck & Co., Global, Late-Stage Pipeline, 2017 25
  • Table 6: Major Products, Sanofi, Global, 2017 31
  • Table 7: Late-Stage Pipeline, Sanofi, Global, 2015 32
  • Table 8: Major Products, Novartis, Global, 2017 38
  • Table 9: Late-Stage Pipeline, Novartis, Global, 2017 39
  • Table 10: Pharmaceutical Market, Valeant, Global, Major Products, 2017 46
  • Table 11: Pharmaceutical Market, Valeant, Global, Late-Stage Pipeline, 2017 47
  • Table 12: Market Access, Singapore, MediSave Wage Contribution (%), 2014 57
  • Table 13: Market Access, Singapore, MediShield Premium Payment Scheme by Age Group ($), 2015 58
  • Table 14: Market Access, Singapore, Medisave-Approved Integrated Shield Plans Withdrawal Limit by Age Group ($), 2014 59
  • Table 15: Market Access, Singapore, Additional Withdrawal Limit by Age Group ($), 2015 59
  • Table 16: Healthcare Expenditure, Singapore, Out-of-Pocket Expenditure (%), 2009-2016 61
  • Table 17: Market Access, Singapore, Healthcare Consumer Price Index Annual Change (%), 2009-2015 62
  • Table 18: Market Access, Singapore, RegistrationDossier Format, 2016 68
  • Table 19: Market Access, Singapore, Registration Dossier Format, 2016 69
  • Table 20: Market Access, Singapore, Registration Dossier Format, 2016 71
  • Table 21: Market Access, Singapore, GMP Certificate Fees for Medicinal Products and Active Pharmaceutical Ingredients ($), 2016 74
  • Table 22: Market Access, Singapore, Manufacturer's License Fees for Medicinal Products ($), 2016 74
  • Table 23: Market Access, Singapore, Manufacturer's License Fees for Medicinal Products ($), 2016 76
  • Table 24: Market Access, Singapore, Wholesale Dealer's License Fees for Medicinal Products ($), 2016 76
  • Table 25: Market Access, Singapore, Patent Co-operation Treaty, International Application Process, 2014 82
  • Table 26: Market Access, Singapore, Patent Filing Fees and Charges, 2017 83
  • Table 27: Market Access, Singapore, Clinical Trial Certificates Issued, 2009-2015 90
  • Table 28: Market Access, Singapore, Clinical Trials by Therapeutic Area (%), 2015 91
  • Table 29: Market Access, Singapore, Target Processing Timelines of Clinical Trial, 2016 92
  • Table 30: Market Access, Singapore, Fees for Advertisement Permit ($), 2016 93
  • Table 31: Market Access, Singapore, Labeling Requirements, 2014 96
  • Table 32: Economic Indicators, Singapore, GDP per Capita ($), 2009-2016 105
  • Table 33: Economic Indicators, Singapore, GDP per Capita ($), 2017-2021 106
  • Table 34: Economic Indicators, Singapore, GDP Annual Growth (%), 2009-2016 107
  • Table 35: Economic Indicators, Singapore, GDP Annual Growth (%), 2017-2021 108
  • Table 36: Economic Indicators, Singapore, GNI per Capita ($), 2009-2016 109
  • Table 37: Economic Indicators, Singapore, Consumer Price Index, 2009-2016 110
  • Table 38: Economic Indicators, Singapore, Average Consumer Price Index, 2017-2021 111
  • Table 39: Economic Indicators, Singapore, Average Consumer Price Index Annual Change (%), 2009-2016 112
  • Table 40: Economic Indicators, Singapore, Average Consumer Price Index, Annual Change (%), 2017-2021 113
  • Table 41: Economic Indicators, Singapore, Currency Exchange Rate (SGD/$), 2009-2016 114
  • Table 42: Economic Indicators, Singapore, Foreign Direct Investment ($bn), 2009-2016 115
  • Table 43: Economic Indicators, Singapore, Foreign Exchange Reserves ($bn), 2009-2016 116
  • Table 44: Economic Indicators, Singapore, Imports of Goods and Services ($bn), 2009-2016 117
  • Table 45: Economic Indicators, Singapore, Exports of Goods and Services ($bn), 2009-2016 118
  • Table 46: Economic Indicators, Singapore, General Government Structural Balance ($bn), 2009-2016 119
  • Table 47: Economic Indicators, Singapore, Government Net Debt as a Percentage of GDP (%), 2009-2016 120
  • Table 48: Economic Indicators, Singapore, Government Net Debt as a Percentage of GDP (%), 2017-2021 121
  • Table 49: Economic Indicators, Singapore, Value Added by Major Industries ($bn), 2015 122
  • Table 50: Demographics, Singapore, Population (million), 2009-2016 124
  • Table 51: Demographics, Singapore, Population (million), 2017-2021 125
  • Table 52: Demographics, Singapore, Urban-Rural Population Share (%), 2009-2016 126
  • Table 53: Demographics, Singapore, Urban-Rural Population Share (%), 2017-2021 127
  • Table 54: Demographics, Singapore, Population Distribution by Age Group (%), 2009-2016 128
  • Table 55: Demographics, Singapore, Population Distribution by Age Group (%), 2017-2021 129
  • Table 56: Demographics, Singapore, Births (per 1,000 Population), 2009-2016 130
  • Table 57: Demographics, Singapore, Mortality (per 1,000 Population), 2009-2016 131
  • Table 58: Demographics, Singapore, Major Causes of Mortality (%), 2015 132
  • Table 59: Demographics, Singapore, Mortality Rate of Children Under Five (per 1,000 live births), 2009-2016 133
  • Table 60: Demographics, Singapore, Immunization Rate (%), 2009-2016 134
  • Table 61: Demographics, Singapore, Major Causes of Male Mortality ('000), 2015 135
  • Table 62: Demographics, Singapore, Major Causes of Female Mortality ('000), 2015 136
  • Table 63: Demographics, Singapore, Gender Ratio (M/F), 2009-2016 137
  • Table 64: Demographics, Singapore, Life Expectancy at Birth (years), 2009-2016 138
  • Table 65: Demographics, Singapore, Life Expectancy at Birth (years), 2017-2021 139
  • Table 66: Demographics, Singapore, Student Enrollment by Level of Education (%), 2015 140
  • Table 67: Demographics, Singapore, Unemployment Rate (%), 2009-2016 141
  • Table 68: Demographics, Singapore, Disability-Adjusted Life Years by Major Disease ('000), 2015 142
  • Table 69: Healthcare Infrastructure, Singapore, Hospitals, 2009-2016 144
  • Table 70: Healthcare Infrastructure, Singapore, Public and Private Hospitals, 2009-2016 145
  • Table 71: Healthcare Infrastructure, Singapore, Hospitals Beds by Sector, 2009-2016 146
  • Table 72: Healthcare Infrastructure, Singapore, Hospitals Beds (per 1,000 population), 2009-2016 147
  • Table 73: Healthcare Infrastructure, Singapore, Doctors (per 1,000 population), 2009-2016 148
  • Table 74: Healthcare Infrastructure, Singapore, PM2.5 (µg per m³), 2009-2016 149
  • Table 75: Healthcare Infrastructure, Singapore, CO2 Emissions (metric tons per capita), 2009-2016 150
  • Table 76: Healthcare Infrastructure, Singapore, Nurses (per 1,000 population), 2009-2016 151
  • Table 77: Healthcare Infrastructure, Singapore, Pharmacists, 2009-2016 152
  • Table 78: Healthcare Infrastructure, Singapore, Dentists, 2009-2016 153
  • Table 79: Healthcare Infrastructure, Singapore, Healthcare Expenditure as Percentage of GDP (%), 2009-2016 154
  • Table 80: Healthcare Infrastructure, Singapore, Public-Private Share of Expenditure (%), 2009-2016 155
  • Table 81: Healthcare Infrastructure, Singapore, Major Components of Healthcare Expenditure (%), 2016 156
  • Table 82: Healthcare Infrastructure, Singapore, R&D Expenditure ($m), 2009-2016 157
  • Table 83: Healthcare Expenditure, Singapore, Major Healthcare Trade Fairs, 2017 160

List of Figures

1.2 List of Figures

  • Figure 1: Pharmaceutical Market, Singapore, Revenue ($bn), 2009-2021 9
  • Figure 2: Country Profile, Singapore, 2017 11
  • Figure 3: Pharmaceutical Market, Singapore, Revenue ($m), 2009-2016 15
  • Figure 4: Pharmaceutical Market, Singapore, Revenue ($m), 2017-2021 16
  • Figure 5: Pharmaceutical Market, Singapore, Exports and Imports ($bn), 2009-2016 17
  • Figure 6: Pharmaceutical Market, Singapore, Distribution Channels (%), 2016 18
  • Figure 7: Healthcare Market, Singapore, Drivers and Barriers, 2017 53
  • Figure 8: Market Access, Singapore, Healthcare Insurance System, 2015 55
  • Figure 9: Market Access, Singapore, Healthcare Financing System, 2015 56
  • Figure 10: Healthcare Expenditure, Singapore, Out-of-Pocket Expenditure (%), 2009-2016 61
  • Figure 11: Market Access, Singapore, Healthcare Consumer Price Index Annual Change (%), 2009-2015 62
  • Figure 12: Market Access, Singapore, Organizational Structure of Drug Regulatory Authority, 2016 63
  • Figure 13: Market Access, Singapore, Structure of Health Sciences Authority, 2014 65
  • Figure 14: Market Access, Singapore, New Drug Application Types, 2014 67
  • Figure 15: Market Access, EU, Centralized Procedure for Market Authorization, Pre-submission, 2016 70
  • Figure 16: Market Access, EU, Conformity Assessment of Class I Medical Devices, 2016 74
  • Figure 17: : Market Access, Singapore, Licensing Process for Import/Export, 2016 76
  • Figure 18: Market Access, Singapore, National Patent Approval Process, 2017 80
  • Figure 19: Market Access, Singapore, Patent Co-operation Treaty National Phase Entry Process, 2016 81
  • Figure 20: Market Access, Singapore, International Patent Approval Process, 2016 82
  • Figure 21: Market Access, Singapore, National Trademark Approval Process, 2017 87
  • Figure 22: Market Access, Singapore, International Trademark Approval Process, 2017 88
  • Figure 23: Market Access, Singapore, Clinical Trial Certificates Issued, 2009-2015 90
  • Figure 24: Market Access, Singapore, Clinical Trials by Therapeutic Area (%), 2015 91
  • Figure 25: Economic Indicators, Singapore, GDP Per Capita ($), 2009-2016 105
  • Figure 26: Economic Indicators, Singapore, GDP per Capita ($), 2017-2021 106
  • Figure 27: Economic Indicators, Singapore, GDP Annual Growth (%), 2009-2016 107
  • Figure 28: Economic Indicators, Singapore, GDP Annual Growth (%), 2017-2021 108
  • Figure 29: Economic Indicators, Singapore, GNI per Capita ($), 2009-2016 109
  • Figure 30: Economic Indicators, Singapore, Consumer Price Index, 2009-2016 110
  • Figure 31: Economic Indicators, Singapore, Average Consumer Price Index, 2017-2021 111
  • Figure 32: Economic Indicators, Singapore, Average Consumer Price Index, Annual Change (%), 2009-2016 112
  • Figure 33: Economic Indicators, Singapore, Average Consumer Price Index, Annual Change (%), 2017-2021 113
  • Figure 34: Economic Indicators, Singapore, Currency Exchange Rate (SGD/$), 2009-2016 114
  • Figure 35: Economic Indicators, Singapore, Foreign Direct Investment ($bn), 2009-2016 115
  • Figure 36: Economic Indicators, Singapore, Foreign Exchange Reserves ($bn), 2009-2016 116
  • Figure 37: Economic Indicators, Singapore, Imports of Goods and Services ($bn), 2009-2016 117
  • Figure 38: Economic Indicators, Singapore, Exports of Goods and Services ($bn), 2009-2016 118
  • Figure 39: Economic Indicators, Singapore, Government Structural Balance ($bn), 2009-2016 119
  • Figure 40: Economic Indicators, Singapore, Government Net Debt as a Percentage of GDP (%), 2009-2016 120
  • Figure 41: Economic Indicators, Singapore, Government Net Debt as a Percentage of GDP (%), 2017-2021 121
  • Figure 42: Economic Indicators, Singapore, Value Added by Major Industries ($bn), 2015 122
  • Figure 43: Demographics, Singapore, Population (million), 2009-2016 124
  • Figure 44: Demographics, Singapore, Population (million), 2017-2021 125
  • Figure 45: Demographics, Singapore, Urban-Rural Population Share (%), 2009-2016 126
  • Figure 46: Demographics, Singapore, Urban-Rural Population Share (%), 2017-2021 127
  • Figure 47: Demographics, Singapore, Population Distribution by Age Group (%), 2009-2016 128
  • Figure 48: Demographics, Singapore, Population Distribution by Age Group (%), 2017-2021 129
  • Figure 49: Demographics, Singapore, Births (per 1,000 Population), 2009-2016 130
  • Figure 50: Demographics, Singapore, Mortality (per 1,000 Population), 2009-2016 131
  • Figure 51: Demographics, Singapore, Major Causes of Mortality (%), 2015 132
  • Figure 52: Demographics, Singapore, Mortality Rate of Children Under Five (per 1,000 live births), 2009-2016 133
  • Figure 53: Demographics, Singapore, Immunization Rate (%), 2009-2016 134
  • Figure 54: Demographics, Singapore, Major Causes of Male Mortality ('000), 2015 135
  • Figure 55: Demographics, Singapore, Major Causes of Female Mortality ('000), 2015 136
  • Figure 56: Demographics, Singapore, Gender Ratio (M/F), 2009-2016 137
  • Figure 57: Demographics, Singapore, Life Expectancy at Birth (years), 2009-2016 138
  • Figure 58: Demographics, Singapore, Life Expectancy at Birth (years), 2017-2021 139
  • Figure 59: Demographics, Singapore, Student Enrollment by Level of Education (%), 2015 140
  • Figure 60: Demographics, Singapore, Unemployment Rate (%), 2009-2016 141
  • Figure 61: Demographics, Singapore, Major Diseases, Disability-Adjusted Life Years by Major Disease ('000s), 2015 142
  • Figure 62: Healthcare Infrastructure, Singapore, Hospitals, 2009-2016 144
  • Figure 63: Healthcare Infrastructure, Singapore, Public and Private Hospitals, 2009-2016 145
  • Figure 64: Healthcare Infrastructure, Singapore, Hospitals Beds by Sector, 2009-2016 146
  • Figure 65: Healthcare Infrastructure, Singapore, Hospitals Beds (per 1,000 population), 2009-2016 147
  • Figure 66: Healthcare Infrastructure, Singapore, Doctors (per 1,000 population), 2009-2016 148
  • Figure 67: Healthcare Infrastructure, Singapore, PM2.5 (µg per m³), 2009-2016 149
  • Figure 68: Healthcare Infrastructure, Singapore, CO2 Emissions (metric tons per capita), 2009-2016 150
  • Figure 69: Healthcare Infrastructure, Singapore, Nurses (per 1,000 population), 2009-2016 151
  • Figure 70: Healthcare Infrastructure, Singapore, Pharmacists, 2009-2016 152
  • Figure 71: Healthcare Infrastructure, Singapore, Dentists, 2009-2016 153
  • Figure 72: Healthcare Infrastructure, Singapore, Healthcare Expenditure as Percentage of GDP (%), 2009-2016 154
  • Figure 73: Healthcare Infrastructure, Singapore, Public-Private Share of Expenditure (%), 2009-2016 155
  • Figure 74: Healthcare Infrastructure, Singapore, Major Components of Healthcare Expenditure (%), 2016 156
  • Figure 75: Healthcare Infrastructure, Singapore, R&D Expenditure ($m), 2009-2016 157
  • Figure 76: Healthcare Market, Singapore, Opportunities and Challenges, 2016 162
Back to Top